Inflammasome functional activities in B lymphocytes.
Adaptive immunity
B cell
Inflammasome
Innate immunity
NLRP3
Journal
Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
09
04
2024
accepted:
08
05
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
22
5
2024
Statut:
aheadofprint
Résumé
Studies in animal models and human subjects have shown that, in addition to their implication in innate immunity, inflammasomes also can play a role in adaptive immunity. However, the contribution of the nucleotide-binding oligomerization domain-, leucine-rich repeat-, and pyrin domain-containing protein 3 (NLRP3) inflammasome pathway to adaptive immunity remains incompletely explored. Here, we show that NLRP3 plays an important role in different facets of B cell functions, including proliferation, antibody production, and secretion of inflammatory and anti-inflammatory cytokines. When exposed to B cell receptor engagement, Toll-like receptor activation, stimulation in conditions that mimic T cell-dependent responses, or NLRP3 activation, B cells manifest disparate responses and produce different cytokine patterns critical for modulating innate and adaptive immunity, indicating that the cytokines produced serve a critical link between the early innate immune response and the delayed adaptive immunity. Importantly, genetic ablation of nlrp3 reduced the inflammasome-mediated functions of B cells. We propose that, in the absence of other cell types, the potential of B lymphocytes to respond to NLRP3 engagement enables them to initiate inflammatory cascades through recruitment of other cell subsets, such as macrophages and neutrophils. Since NLRP3 activation of B cells is not followed by pyroptosis, even in the presence of a basal caspase-1 activity, this pathway acts as a bridge that optimizes interactions between the innate and adoptive branches of the immune response.
Identifiants
pubmed: 38777958
doi: 10.1007/s12026-024-09490-9
pii: 10.1007/s12026-024-09490-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296:298–300.
doi: 10.1126/science.1068883
pubmed: 11951031
Farber DL, Netea MG, Radbruch A, Rajewsky K, Zinkernagel RM. Immunological memory: lessons from the past and a look to the future. Nat Rev Immunol. 2016;16:124–8.
doi: 10.1038/nri.2016.13
pubmed: 26831526
He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41:1012–21.
doi: 10.1016/j.tibs.2016.09.002
pubmed: 27669650
pmcid: 5123939
Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.
doi: 10.1038/s41577-019-0165-0
pubmed: 31036962
pmcid: 7807242
Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Vegran F, Ghiringhelli F. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol. 2015;16:859–70.
doi: 10.1038/ni.3202
pubmed: 26098997
Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, Dutow P, Woodruff TM, Yu ZX, O’Neill LA, Coll RC, Sher A, Leonard WJ, Kohl J, Monk P, Cooper MA, Arno M, Afzali B, Lachmann HJ, Cope AP, Mayer-Barber KD, Kemper C. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science. 2016;352:aad1210.
doi: 10.1126/science.aad1210
pubmed: 27313051
pmcid: 5015487
Martin BN, Wang C, Zhang CJ, Kang Z, Gulen MF, Zepp JA, Zhao J, Bian G, Do JS, Min B, Pavicic PG Jr., El-Sanadi C, Fox PL, Akitsu A, Iwakura Y, Sarkar A, Wewers MD, Kaiser WJ, Mocarski ES, Rothenberg ME, Hise AG, Dubyak GR, Ransohoff RM, Li X. T cell-intrinsic ASC critically promotes T(H)17-mediated experimental autoimmune encephalomyelitis. Nat Immunol. 2016;17:583–92.
doi: 10.1038/ni.3389
pubmed: 26998763
pmcid: 5385929
Park SH, Ham S, Lee A, Moller A, Kim TS. NLRP3 negatively regulates Treg differentiation through Kpna2-mediated nuclear translocation. J Biol Chem. 2019;294:17951–61.
doi: 10.1074/jbc.RA119.010545
pubmed: 31597697
pmcid: 6879348
Kumar H, Kumagai Y, Tsuchida T, Koenig PA, Satoh T, Guo Z, Jang MH, Saitoh T, Akira S, Kawai T. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol. 2009;183:8061–7.
doi: 10.4049/jimmunol.0902477
pubmed: 20007575
Ali MF, Driscoll CB, Walters PR, Limper AH, Carmona EM. Beta-glucan-activated human B lymphocytes participate in innate immune responses by releasing proinflammatory cytokines and stimulating neutrophil chemotaxis. J Immunol. 2015;195:5318–26.
doi: 10.4049/jimmunol.1500559
pubmed: 26519534
Lim KH, Chen LC, Hsu K, Chang CC, Chang CY, Kao CW, Chang YF, Chang MC, Chen CG. BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death Dis. 2020;11:820.
doi: 10.1038/s41419-020-03035-2
pubmed: 33004801
pmcid: 7529748
Leal VNC, Reis EC, Fernandes FP, Soares J, Oliveira IGC, de Souza D, Lara AN, Lopes MH, Pontillo A. Common pathogen-associated molecular patterns induce the hyper-activation of NLRP3 inflammasome in circulating B lymphocytes of HIV-infected individuals. AIDS. 2021;35:899–910.
doi: 10.1097/QAD.0000000000002833
pubmed: 33821820
Hsu ML, Zouali M. Inflammasome is a central player in B cell development and homing. Life Sci Alliance. 2022;6(2):e202201700. https://doi.org/10.26508/lsa.202201700 .
Zouali M. Swaying the advantage: multifaceted functions of inflammasomes in adaptive immunity. FEBS J. 2024. (in press)
Kovarova M, Hesker PR, Jania L, Nguyen M, Snouwaert JN, Xiang Z, Lommatzsch SE, Huang MT, Ting JP, Koller BH. NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J Immunol. 2012;189:2006–16.
doi: 10.4049/jimmunol.1201065
pubmed: 22753929
Viau M, Longo NS, Lipsky PE, Zouali M. Staphylococcal protein a deletes B-1a and marginal zone B lymphocytes expressing human immunoglobulins: an immune evasion mechanism. J Immunol. 2005;175:7719–27.
doi: 10.4049/jimmunol.175.11.7719
pubmed: 16301682
Locovei S, Scemes E, Qiu F, Spray DC, Dahl G. Pannexin1 is part of the pore forming unit of the P2X(7) receptor death complex. FEBS Lett. 2007;581:483–8.
doi: 10.1016/j.febslet.2006.12.056
pubmed: 17240370
pmcid: 1868681
Mariathasan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440:228–32.
doi: 10.1038/nature04515
pubmed: 16407890
Pelegrin P, Surprenant A. Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem. 2007;282:2386–94.
doi: 10.1074/jbc.M610351200
pubmed: 17121814
Falkoff RJ, Muraguchi A, Hong JX, Butler JL, Dinarello CA, Fauci AS. The effects of interleukin 1 on human B cell activation and proliferation. J Immunol. 1983;131:801–5.
doi: 10.4049/jimmunol.131.2.801
pubmed: 6602846
Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003–18.
doi: 10.1016/j.immuni.2013.11.010
pubmed: 24332029
pmcid: 3933951
Cibrian D, Sanchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47:946–53.
doi: 10.1002/eji.201646837
pubmed: 28475283
pmcid: 6485631
Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233–58.
doi: 10.1146/annurev.immunol.14.1.233
pubmed: 8717514
Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Munoz-Arias I, Greene WC. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505:509–14.
doi: 10.1038/nature12940
pubmed: 24356306
pmcid: 4047036
Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–8.
doi: 10.4049/jimmunol.172.5.2731
pubmed: 14978070
Zouali M. Transcriptional and metabolic pre-B cell receptor-mediated checkpoints: implications for autoimmune diseases. Mol Immunol. 2014;62:315–20.
doi: 10.1016/j.molimm.2014.01.009
pubmed: 24602812
Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:540–3.
doi: 10.1126/science.275.5299.540
pubmed: 8999800
Lucas CR, Cordero-Nieves HM, Erbe RS, McAlees JW, Bhatia S, Hodes RJ, Campbell KS, Sanders VM. Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. J Immunol. 2013;190:723–36.
doi: 10.4049/jimmunol.1201646
pubmed: 23241883
Liu H, Fan H, He P, Zhuang H, Liu X, Chen M, Zhong W, Zhang Y, Zhen C, Li Y, Jiang H, Meng T, Xu Y, Zhao G, Feng D. Prohibitin 1 regulates mtDNA release and downstream inflammatory responses. EMBO J. 2022;41:e111173.
doi: 10.15252/embj.2022111173
pubmed: 36245295
pmcid: 9753472
Inoue M, Williams KL, Gunn MD, Shinohara ML. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2012;109:10480–5.
doi: 10.1073/pnas.1201836109
pubmed: 22699511
pmcid: 3387125
Liu H, Xu R, Kong Q, Liu J, Yu Z, Zhao C. Downregulated NLRP3 and NLRP1 inflammasomes signaling pathways in the development and progression of type 1 diabetes mellitus. Biomed Pharmacother. 2017;94:619–26.
doi: 10.1016/j.biopha.2017.07.102
pubmed: 28783585
Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 2018;17:588–606.
doi: 10.1038/nrd.2018.97
pubmed: 30026524
Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Nunez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O’Neill LA. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248–55.
doi: 10.1038/nm.3806
pubmed: 25686105
pmcid: 4392179